Norgine announces hepatic encephalopathy study

Independent European pharma company Norgine has presented the study design of its PROSPER trial, a real-world outcomes study of hepatic encephalopathy patients’ experiences on rifaximin-α at the International Liver Congress 2015.

It is an observational, multicenter study of 550 patients in Europe and Australia, designed to monitor the clinical effectiveness of rifaximin-α  and its impact on healthcare resources.

The condition places a serious burden on patients and their caregivers, and the burden increases as the disease progresses. Patients with hepatic encephalopathy have significantly more hospitalizations and primary care contacts compared with patients with severe liver disease without hepatic encephalopathy.